MedTrace Logo

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05866692 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2023-11-07

No results posted yet for this study

Summary

This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

TY-2699a

TY-2699a PO, BID Escalation stage: increased dose cohorts from low dose to MTD Expansion stage: The dose for the Expansion stage will be determined based on results

Sponsors & Collaborators

  • TYK Medicines, Inc

    lead INDUSTRY

Principal Investigators

  • TYK Medicines, Inc · TYK Medicines, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2025-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05866692 on ClinicalTrials.gov